New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in obese patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone1.
This entry was posted
on Sunday, September 7th, 2008 at 7:00 am and is filed under Cholesterol.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
